Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. (Articolo in rivista)

Type

• Articolo in rivista (Classe)
• Prodotto della ricerca (Classe)

Label

• Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. (Articolo in rivista) (literal)

Anno

• 2006-01-01T00:00:00+01:00 (literal)

Alternative label

• Carai M.A.M., Colombo G., Maccioni P., Gessa G.L (2006)
  Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.
  in CNS drug reviews
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Carai M.A.M., Colombo G., Maccioni P., Gessa G.L (literal)

Pagina inizio

• 91 (literal)

Pagina fine

• 99 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 12 (literal)

Rivista

• CNS drug reviews (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali

• 9 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

• 2 (literal)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• C.N.R. Institute of Neuroscience, Cagliari, Italy; \"Bernard B. Brodie\" Department of Neuroscience, University of Cagliari, Italy (literal)

Titolo

• Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. (literal)

Abstract

• The present paper focuses on the different lines of evidence indicating that cannabinoid CB1 receptor antagonists, including the prototype rimonabant, reduce food intake and body weight in laboratory animals. Recent clinical surveys demonstrated that rimonabant significantly reduced body weight also in overweight/obese humans. Treatment with rimonabant was associated with a beneficial effect on different metabolic parameters and cardiovascular risk factors linked to overweight. The data reviewed in this paper suggest that cannabinoid CB1 receptor antagonists may constitute a novel class of drugs potentially effective in the treatment of obesity-related disorders. (literal)

Prodotto di

• Neurobiologia dell'alcolismo (ME.P02.020.001) (Modulo)
• Istituto di neuroscienze (IN) (Istituto)

Autore CNR

• GIAN LUIGI GESSA (Unità di personale esterno)
• GIANCARLO COLOMBO (Unità di personale interno)

Insieme di parole chiave

• Parole chiave di "Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data." (Insieme di parole chiave)

Incoming links:

Autore CNR di

• GIANCARLO COLOMBO (Unità di personale interno)
• GIAN LUIGI GESSA (Unità di personale esterno)

Prodotto

• Istituto di neuroscienze (IN) (Istituto)
• Neurobiologia dell'alcolismo (ME.P02.020.001) (Modulo)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• CNS drug reviews (Rivista)

Insieme di parole chiave di

• Parole chiave di "Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data." (Insieme di parole chiave)